Nasus Pharma Statistics
Total Valuation
Nasus Pharma has a market cap or net worth of $34.08 million. The enterprise value is $33.07 million.
Important Dates
The last earnings date was Wednesday, March 25, 2026, before market open.
| Earnings Date | Mar 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nasus Pharma has 11.71 million shares outstanding. The number of shares has increased by 15.11% in one year.
| Current Share Class | 11.71M |
| Shares Outstanding | 11.71M |
| Shares Change (YoY) | +15.11% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 34.17% |
| Owned by Institutions (%) | 4.93% |
| Float | 5.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 10.36 |
| P/TBV Ratio | 13.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.24, with a Debt / Equity ratio of 0.04.
| Current Ratio | 2.24 |
| Quick Ratio | 1.98 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -107.15% |
| Return on Invested Capital (ROIC) | -415.31% |
| Return on Capital Employed (ROCE) | -172.62% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$836,571 |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 3.51 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 48.45 |
| Average Volume (20 Days) | 110,800 |
Short Selling Information
The latest short interest is 64,912, so 0.55% of the outstanding shares have been sold short.
| Short Interest | 64,912 |
| Short Previous Month | 11,380 |
| Short % of Shares Out | 0.55% |
| Short % of Float | 1.18% |
| Short Ratio (days to cover) | 0.14 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -4.90M |
| Pretax Income | -5.81M |
| Net Income | -5.86M |
| EBITDA | n/a |
| EBIT | -4.90M |
| Earnings Per Share (EPS) | -$0.73 |
Full Income StatementBalance Sheet
The company has $4.29 million in cash and $118,000 in debt, giving a net cash position of $4.17 million or $0.36 per share.
| Cash & Cash Equivalents | 4.29M |
| Total Debt | 118,000 |
| Net Cash | 4.17M |
| Net Cash Per Share | $0.36 |
| Equity (Book Value) | 2.77M |
| Book Value Per Share | 0.31 |
| Working Capital | 2.69M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.92 million and capital expenditures -$14,000, giving a free cash flow of -$4.93 million.
| Operating Cash Flow | -4.92M |
| Capital Expenditures | -14,000 |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -4.93M |
| FCF Per Share | -$0.42 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |